Maternal Vaccines Protecting Newborns Before Birth and Expanding Access Worldwide
A baby’s first protection from infection can begin before the first breath. During pregnancy, antibodies made by the mother can cross the placenta and help shield the newborn in the fragile early weeks of life. Maternal vaccines use this natural pathway, turning routine antenatal care into one of the earliest and most powerful tools for child survival.
This matters because newborns do not enter the world with fully developed immune systems. Many routine childhood vaccines start after birth, and some require multiple doses before strong protection builds. That leaves a gap, especially in the first months, when infections such as tetanus, pertussis, influenza, and respiratory viruses can be dangerous.
Maternal vaccination helps close that gap. It can protect pregnant women, reduce severe illness, and pass antibodies to infants when they need them most. For countries working to reduce newborn deaths, maternal vaccines are not a side issue. They are central to protecting newborns and infants before disease has a chance to take hold.
How maternal vaccines protect babies before birth
Maternal vaccines work by prompting the pregnant person’s immune system to make antibodies against a specific infection. These antibodies then pass through the placenta to the baby, mainly in the later months of pregnancy. After birth, some antibodies may also be shared through breast milk, although the level and type of protection vary by disease.
The goal is simple: protect two lives through one health intervention.
For the mother, vaccination can lower the risk of severe disease during pregnancy. That is especially valuable because pregnancy changes the immune, heart, and lung systems. Some infections can become more serious during this period, and illness in the mother can also affect the baby.
For the infant, maternal antibodies provide early defence before the baby can build their own immunity through routine immunisation. This does not replace childhood vaccination. It complements it. Maternal vaccination covers the early window, while infant vaccination builds longer-term protection.
Several maternal vaccines already play an important role in public health.
Tetanus-containing vaccines have long been used in pregnancy to prevent maternal and neonatal tetanus. Neonatal tetanus can occur when birth or cord care takes place in unhygienic conditions. It is often fatal without advanced care, yet it is preventable through clean delivery practices and vaccination.
Influenza vaccines can protect pregnant women from flu complications and reduce influenza illness in young infants. Infants under six months are usually too young for flu vaccination, so maternal immunisation can help bridge that period.
Pertussis vaccines, often given as Tdap in pregnancy, protect babies against whooping cough. This is important because pertussis can be especially severe in very young infants, sometimes before they are old enough to complete their own vaccine schedule.
COVID-19 vaccination during pregnancy has also become part of maternal health recommendations in many settings, especially for reducing severe illness. Evidence from immunisation programmes has shown that antibodies can pass to infants, though policies differ by country and risk group.
New maternal vaccines are also changing the field. Respiratory syncytial virus, known as RSV, is a major cause of lower respiratory infection in infants. Maternal RSV vaccination has been introduced or recommended in some countries, adding a new option to protect babies during their earliest months.
Why pregnancy is a critical window for prevention
Pregnancy is one of the few times when health systems already have repeated contact with families before a child is born. Antenatal visits offer opportunities for screening, counselling, nutrition support, birth planning, and vaccination.
When maternal vaccines are included in antenatal care, they can reach babies before birth and mothers before infection strikes. This can reduce:
Severe illness during pregnancy
Preterm birth linked to some infections
Hospital visits for newborns
Deaths from vaccine-preventable diseases
Emotional and financial strain on families
The benefits are not only medical. In many communities, a newborn’s illness can push families into debt because of transport, hospital care, medicines, and lost wages. Preventing illness early can help protect household stability.
This is especially relevant in India and other countries with large birth cohorts. Even a modest improvement in protection during pregnancy can affect many families. Strong maternal immunisation can also support national goals on newborn survival, safe motherhood, and universal health coverage.
Antenatal care is already trusted in many communities, but trust must be earned. Pregnant women and families need clear information about why a vaccine is recommended, when it should be given, what side effects to expect, and how it protects both mother and baby.
The access gap in low- and middle-income countries
The promise of maternal vaccines is clear, but access is uneven. Low- and middle-income countries often face the highest burden of newborn infections and the greatest strain in introducing new vaccines.
One challenge is the cost of new vaccines. A vaccine may be available in wealthier countries but remain unaffordable for public programmes elsewhere. Maternal RSV vaccines, for example, raise important questions about financing, supply, and delivery in countries where infant respiratory disease places a heavy burden on hospitals.
Another challenge is delivery. Childhood immunisation often has a defined system, with clear schedules and dedicated vaccination days. Maternal immunisation sits between immunisation services and antenatal care. If these systems do not communicate well, pregnant women may miss vaccines even when they attend check-ups.
Health worker training is also critical. Nurses, midwives, community health workers, and doctors need practical guidance on vaccine timing, eligibility, contraindications, record-keeping, and counselling. If health workers feel unsure, coverage suffers.
Supply chains can be another weak point. Vaccines need cold-chain storage, transport, stock monitoring, and timely distribution. Rural and hard-to-reach areas may face stock-outs, power issues, and transport delays. Even when a policy exists at national level, a missing vial at the clinic means a missed opportunity.
Data gaps make planning harder. Countries need to know how many pregnant women are being vaccinated, where gaps are largest, and whether safety monitoring systems are picking up and responding to concerns. Many health information systems were built around infant vaccination, not pregnancy-based vaccination.
Then there is the challenge of vaccine confidence. Misinformation can spread quickly, especially when the word “pregnancy” is involved. Families may worry about safety, fertility, side effects, or harm to the baby. Silence from health systems leaves room for rumours. Clear, respectful communication is essential.
Maternal vaccines succeed when they are treated not as an add-on, but as part of quality antenatal care.
What successful initiatives teach us
The history of maternal immunisation offers strong lessons. The best-known example is the global effort to reduce maternal and neonatal tetanus. Through tetanus vaccination for women of reproductive age, clean birth practices, safer cord care, and community outreach, many countries have eliminated maternal and neonatal tetanus as a public health problem.
This achievement did not come from vaccines alone. It came from combining vaccination with skilled birth attendance, clean delivery kits, surveillance, and local health education. It also showed that community health workers can play a major role in reaching women who do not regularly use facility-based care.
Pertussis vaccination during pregnancy offers another lesson. Countries that introduced maternal Tdap programmes found that timing matters. Vaccination must take place early enough in the recommended window for antibodies to build and pass to the baby. Programmes also learned that health worker recommendation is one of the strongest drivers of acceptance. When a trusted provider explains the benefit clearly, uptake improves.
Influenza vaccination in pregnancy shows the importance of risk communication. Flu can be dismissed as mild, yet it can be serious during pregnancy. Countries that integrate flu vaccination into antenatal services, rather than leaving it as a separate seasonal campaign, often make it easier for pregnant women to receive it.
COVID-19 vaccination highlighted both the power and the fragility of public trust. In many places, pregnant women were initially excluded from trials, which created uncertainty. Over time, real-world safety data and professional guidance helped shape recommendations. The experience made one thing clear: pregnant women should not be an afterthought in vaccine research and policy.
New RSV prevention efforts are now testing whether the world can act faster and fairer. If maternal RSV vaccines and other infant protection tools are introduced only in wealthier settings, the global access gap will widen. If countries, donors, manufacturers, and public health agencies plan early, access can be broader from the start.
How to accelerate equitable access
Expanding maternal vaccine access requires more than approval from regulators. Countries need a practical path from policy to protection.
Build maternal immunisation into antenatal care
Vaccination should be offered where pregnant women already receive care. That means antenatal clinics, primary health centres, outreach sessions, and mobile services. The process should be simple: check eligibility, counsel, vaccinate, record, and follow up.
Antenatal cards and digital health records should include maternal vaccines clearly. If a woman moves between facilities, the next provider should know what she has received and what is due.
Finance vaccines before demand outpaces supply
Equitable access depends on early financing. Governments, global health agencies, and donors need to plan for vaccine purchase, delivery costs, health worker training, communication, and safety monitoring.
The purchase price is only one part of the cost. A programme also needs refrigerators, transport, data systems, printed materials, supervision, and time for counselling. Underfunding these basics can weaken even a good policy.
Include pregnant women in research with care
Historically, pregnant women have often been excluded from vaccine trials. This can delay evidence and create uncertainty after a vaccine is introduced. Ethical research can include pregnant women with suitable safeguards, transparent consent, and careful follow-up.
Better evidence helps regulators, health workers, and families make confident decisions. It also helps countries decide which vaccines to prioritise.
Support health workers with practical tools
Health workers need short, clear guidance. They should know:
Which vaccines are recommended during pregnancy
The best timing for each vaccine
How to explain benefits and common side effects
How to respond to safety concerns
How to report adverse events
How to record doses accurately
Training should include midwives, nurses, obstetricians, community health workers, pharmacists, and immunisation staff. Everyone involved should share the same message.
Communicate in local languages and listen first
Vaccine communication must be two-way. Families may ask honest questions, and those questions deserve respectful answers. Messages work best when they are local, simple, and specific.
A good counselling message might explain that the vaccine helps the mother make antibodies, passes some of that protection to the baby before birth, and reduces the risk of severe disease in the early months. It should also explain common side effects, such as mild fever or soreness, and when to seek care.
Community leaders, women’s groups, self-help groups, and frontline workers can help share accurate information. Trust grows when people hear consistent guidance from sources they already know.
Track coverage and safety in real time
Maternal vaccine programmes need reliable data. Countries should track coverage by region, age group, clinic type, and gestational timing where possible. This can show which communities are being missed.
Safety monitoring is just as important. Pregnancy outcomes vary for many reasons, so systems need careful review to understand whether an event is related to vaccination or simply occurred after vaccination. Transparent reporting helps protect trust.
What this means for mothers and babies
Maternal vaccines offer one of the most direct ways to protect health across generations. A vaccine given during pregnancy can reduce the mother’s risk of severe illness and give the baby a safer start. That early protection can mean fewer emergency visits, fewer severe infections, and more stable first weeks at home.
The wider benefits can spread through the health system. Fewer preventable newborn infections can ease pressure on neonatal units and paediatric wards. Families can avoid some medical costs. Health workers can focus limited resources on conditions that cannot yet be prevented.
For low- and middle-income countries, the opportunity is large. Many already have strong experience with antenatal care, community outreach, and childhood immunisation. The task now is to connect these strengths, close financing gaps, and make newer maternal vaccines available without waiting years for access.
This content is for general information only and does not replace medical advice. Vaccine recommendations vary by country, health condition, and stage of pregnancy, so clinical guidance from a qualified health professional remains essential.
The path forward starts before birth
A child’s first days should not be a race against preventable infection. Maternal vaccines give families and health systems a head start. They protect mothers during a vulnerable period and carry protection to babies before birth.
The next step is clear. Countries need to treat maternal immunisation as a core part of antenatal care, not a separate campaign that depends on chance. Global partners need to support fair pricing, steady supply, and early introduction in the places with the greatest need. Health workers need training and trust-building tools. Communities need clear answers, not confusion.
When maternal vaccines reach every pregnancy that can benefit from them, newborn protection begins earlier, families gain confidence, and more babies get the healthy start they deserve.
Comments